Biobanking Market

The biobanking market is projected to reach USD 12.38 billion by 2031, up from USD 8.09 billion in 2026, at a CAGR of 8.9%. Market growth is driven by the increasing adoption of precision medicine and biomarker-driven drug development, along with the growth of cell & gene therapy and other complex biologics manufacturing. Additionally, increasing outsourcing of R&D, laboratory, and sample-management activities supports market growth.

The global biobanking market is highly competitive, with leading players including Thermo Fisher Scientific (US), PHC Holdings Corporation (Japan), Becton, Dickinson and Company (BD) (US), Qiagen (Germany), and Merck KGaA (Germany). Market participants have pursued a range of strategies, including approvals and launches of new products and services, acquisitions, agreements, collaborations, partnerships, and geographic expansions, to strengthen their position in the global biobanking market.

To know about the assumptions considered for the study download the pdf brochure

Thermo Fisher Scientific Inc. (US)

Thermo Fisher Scientific is a leading player in the biobanking market, offering comprehensive solutions spanning sample collection, preparation, storage, transport, analysis, and data management. Its portfolio includes ultra-low-temperature freezers, cryogenic tubes, automated sample storage systems, reagents, and informatics solutions for sample tracking and inventory management. These solutions help biobanks and research organizations preserve biospecimen integrity and improve workflow efficiency.

PHC Holdings Corporation (Japan)

PHC Holdings is a leading player in the biobanking market through its PHCbi business, which provides specialized cold storage and cryopreservation solutions for biological samples. Its portfolio includes ultra-low-temperature and laboratory freezers designed for the long-term storage of sensitive biospecimens, such as blood products, proteins, cells, and other biological materials. The company’s focus on temperature stability, sample protection, and reliable storage infrastructure strengthens its position in biobanking and biomedical research.

Becton, Dickinson and Company (BD) (US)

BD is a key player in the biobanking market, particularly in sample collection, preservation, and preparation technologies. Its portfolio includes BD Vacutainer cell and biomarker preservation tubes, which support the collection, stabilization, processing, transportation, and storage of blood-derived specimens. BD also offers OMICS-Guard preservation solutions that maintain the integrity of single-cell, tissue, and whole-blood samples for downstream transcriptomic, proteomic, and multiomic applications, strengthening its role in advanced biobanking workflows.

QIAGEN (Germany)

QIAGEN is a leading player in the biobanking market, with a strong focus on sample collection, stabilization, preservation, and molecular sample preparation. Its portfolio includes PAXgene, RNAprotect, Allprotect, and QIAcard solutions that enable the collection and stabilization of DNA, RNA, proteins, tissues, blood, saliva, and other biological specimens. These technologies help preserve sample integrity during storage and transport and support downstream genomic and molecular analysis, strengthening QIAGEN’s position in research-oriented biobanking workflows.

Market Ranking

The biobanking market shows moderate consolidation, with leading companies capturing a significant share through broad product portfolios, specialized storage technologies, sample preservation solutions, and integrated biobanking workflows. Competitive positioning is primarily driven by strengths in biological sample collection, preservation, temperature-controlled storage, sample management, molecular preparation, and downstream research applications.

Thermo Fisher Scientific Inc. (US) maintains a strong position through its comprehensive biobanking portfolio, including ultra-low-temperature freezers, cryogenic storage systems, laboratory consumables, sample preparation solutions, and informatics technologies. PHC Holdings Corporation (Japan) strengthens its position through PHCbi’s specialized ultra-low-temperature and cryogenic storage solutions for the long-term preservation of biological specimens. Becton, Dickinson and Company (BD) (US) differentiates itself with sample collection and stabilization technologies, including blood collection systems and preservation solutions that support biospecimen integrity for downstream research. QIAGEN N.V. (Germany) maintains a strong position through sample collection, stabilization, and molecular preparation solutions that preserve DNA, RNA, proteins, tissues, and other biological specimens. Merck KGaA (Germany) supports the market with its broad life science portfolio, including laboratory consumables, reagents, cell culture products, filtration technologies, and sample preparation solutions used across biobanking and biomedical research workflows.

The remaining market comprises specialized biobanking solution providers, laboratory equipment manufacturers, sample management companies, CROs, and emerging technology developers that offer application-specific products and services. These players are expanding through automated sample storage, digital sample tracking, advanced preservation technologies, workflow integration, and collaborations with pharmaceutical and biotechnology companies, academic institutions, hospitals, and research organizations.

Related Reports:

Biobanking Market by Product (Equipment, Consumables), Software, Services, Workflow (Collection, Storage, Transport), Operation, Sample type (Blood, Stem Cells, Nucleic Acid), Application, Ownership, Region, End User, Competition - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]